Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Conrad J Wong

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
The International Journal of Neuropsychopharmacology|February 1, 2015
Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and humanLinda M Rorick-Kehn, Jennifer W Witcher, Stephen L Lowe, et al.
Drug and Alcohol Dependence|August 2, 2011
Randomized multi-site trial of the Job Seekers' Workshop in patients with substance use disordersDace S Svikis, Lori Keyser-Marcus, Maxine Stitzer, et al.
Neuropharmacology|September 28, 2013
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLinda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
The International Journal of Neuropsychopharmacology|February 1, 2015
Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and humanLinda M Rorick-Kehn, Jennifer W Witcher, Stephen L Lowe, et al.
Drug and Alcohol Dependence|August 2, 2011
Randomized multi-site trial of the Job Seekers' Workshop in patients with substance use disordersDace S Svikis, Lori Keyser-Marcus, Maxine Stitzer, et al.
Neuropharmacology|September 28, 2013
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disordersLinda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, et al.
Pageof 4